Abstract
High-dose intravenous therapy with proton-pump inhibitors (PPIs) reduces the risk for rebleeding in patients with bleeding peptic ulcers. Thus, IV PPI therapy is the standard of care for these patients after endoscopy and might also be beneficial before endoscopy. As these benefits have become clear, many hospitals have lifted any initial cost-containment restrictions that they had on IV PPI use. Investigators in Canada set out to determine whether such a shift …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.